According to Smith & Nephew 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.459. At the end of 2013 the company had a P/E ratio of 23.2.
Year | P/E ratio | Change |
---|---|---|
2013 | 23.2 | 70.77% |
2012 | 13.6 | -7.81% |
2011 | 14.8 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 21.0 | -17.56% | ๐บ๐ธ USA |
![]() Boston Scientific BSX | 115 | 353.16% | ๐บ๐ธ USA |
![]() Edwards Lifesciences EW | 34.6 | 36.07% | ๐บ๐ธ USA |
![]() Stryker Corporation SYK | 42.7 | 67.58% | ๐บ๐ธ USA |
![]() Orthofix Medical
OFIX | -7.41 | -129.11% | ๐บ๐ธ USA |
![]() CONMED CNMD | -33.1 | -230.13% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.